E78.2

Mixed hyperlipidemia

## Clinical Overview of Mixed Hyperlipidemia Mixed hyperlipidemia, classified under ICD-10 as E78.2, is a complex metabolic disorder characterized by the simultaneous elevation of serum cholesterol and triglyceride levels. Clinically, this often corresponds to the Fredrickson Type IIb hyperlipoproteinemia phenotype. This condition is a significant contributor to the development of early-onset atherosclerosis and coronary artery disease (CAD). Unlike pure hypercholesterolemia (E78.0) or pure hypertriglyceridemia (E78.1), mixed hyperlipidemia represents a dual burden of lipoprotein abnormalities, involving elevations in low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL). ### Pathophysiology The underlying pathophysiology of mixed hyperlipidemia often involves the hepatic overproduction of apolipoprotein B-100 (ApoB). This protein serves as the structural backbone for VLDL and LDL particles. When the liver produces an excess of ApoB, there is an increased secretion of VLDL into the bloodstream. As VLDL is metabolized by lipoprotein lipase (LPL), it is converted into LDL. Consequently, patients exhibit high levels of both triglyceride-rich VLDL and cholesterol-rich LDL. In many cases, there is also a qualitative change in the LDL particles, shifting toward a 'pattern B' profile characterized by small, dense LDL particles which are highly atherogenic due to their ability to easily penetrate the arterial wall and their susceptibility to oxidation. ### Genetic and Acquired Factors Mixed hyperlipidemia can be primary (genetic) or secondary (acquired). The most common genetic form is Familial Combined Hyperlipidemia (FCHL), which affects approximately 1 in 100 individuals. FCHL is characterized by a variable lipid profile within the same individual over time and among affected family members. Secondary factors frequently exacerbate the condition, including insulin resistance, central obesity, sedentary lifestyle, and high-carbohydrate diets. The presence of metabolic syndrome is a common clinical correlate, where systemic inflammation and hormonal imbalances further impair lipid clearance. ### Diagnostic Criteria and Evaluation Diagnosis is primarily based on a fasting lipid panel showing elevated Total Cholesterol (typically >200 mg/dL), LDL-C (>130 or 160 mg/dL depending on risk factors), and Triglycerides (usually 200–499 mg/dL). Given the complexity of the lipid profile, 'Non-HDL Cholesterol' (Total Cholesterol minus HDL) is often considered a superior marker for risk assessment than LDL-C alone in these patients, as it accounts for the cholesterol carried in VLDL and intermediate-density lipoproteins (IDL). Clinical evaluation should include a thorough family history of premature cardiovascular events and screening for secondary causes such as hypothyroidism, nephrotic syndrome, and obstructive liver disease. ### Standard of Care and Management Management focuses on reducing the risk of Atherosclerotic Cardiovascular Disease (ASCVD). First-line therapy involves intensive therapeutic lifestyle changes, including a Mediterranean or DASH diet, weight loss, and regular aerobic exercise. Pharmacological intervention usually begins with HMG-CoA reductase inhibitors (statins) to lower LDL-C. If triglycerides remain elevated (>200 mg/dL) despite statin therapy and lifestyle changes, clinicians may consider the addition of ezetimibe, fibrates, or high-dose omega-3 fatty acids. Fibrates are particularly effective at lowering triglycerides and increasing HDL-C, though caution is required when combining them with statins due to the increased risk of myopathy. Monitoring liver enzymes and creatine kinase is standard practice during treatment titration.

Clinical Symptoms

  • Asymptomatic (most common presentation)
  • Xanthelasma (yellowish deposits around the eyelids)
  • Corneal arcus (white/gray ring around the cornea in patients <45 years)
  • Eruptive xanthomas (small, red-yellow papules on trunk or extremities)
  • Tendinous xanthomas (rare in mixed types, more common in pure hypercholesterolemia)
  • Chest pain or Angina pectoris (indicating advanced atherosclerosis)
  • Intermittent claudication (indicating peripheral artery disease)
  • Abdominal pain (rare, associated with severe hypertriglyceridemia-induced pancreatitis)

Common Causes

  • Familial Combined Hyperlipidemia (FCHL) - Genetic predisposition
  • Insulin resistance and Type 2 Diabetes Mellitus
  • Obesity, particularly visceral/central adiposity
  • Excessive alcohol consumption
  • High intake of saturated fats, trans fats, and refined sugars
  • Sedentary lifestyle/Lack of physical activity
  • Hypothyroidism
  • Nephrotic syndrome or chronic kidney disease
  • Medications (e.g., glucocorticoids, thiazide diuretics, beta-blockers, estrogens)

Documentation & Coding Tips

Distinguish from simple hypercholesterolemia by explicitly documenting both elevated LDL/Total cholesterol and elevated triglycerides to support E78.2.

Example: Patient with established Type IIb mixed hyperlipidemia presents for follow-up. Most recent lipid panel (05/2023) shows LDL 165 mg/dL and Triglycerides 340 mg/dL. This combination confirms mixed hyperlipidemia (E78.2) rather than pure hypercholesterolemia. Management involves titrating Atorvastatin 40mg and continuing Fenofibrate 145mg for cardiovascular risk reduction.

Billing Focus: Combined lipid elevation (Cholesterol + Triglycerides)

Identify and document phenotypic classifications such as Fredrickson Type IIb or Type III if supported by electrophoresis or clinical presentation.

Example: Clinical diagnosis of Familial Combined Hyperlipidemia (Fredrickson Type IIb) documented based on persistent elevation of both VLDL and LDL. Patient exhibits xanthelasma of the bilateral upper eyelids. Mixed hyperlipidemia (E78.2) is a chronic condition impacting the patient's ASCVD 10-year risk score (calculated at 12.5%).

Billing Focus: Specific phenotype documentation

Clearly link Mixed Hyperlipidemia to secondary manifestations or risks, such as metabolic syndrome or coronary artery disease.

Example: Patient is seen for management of metabolic syndrome including Mixed Hyperlipidemia (E78.2), Type 2 Diabetes (E11.9), and Morbid Obesity (E66.01). The mixed hyperlipidemia significantly complicates the management of his atherosclerotic heart disease (I25.10). Documentation reflects the clinical complexity of managing dual lipid elevations in the presence of metabolic dysfunction.

Billing Focus: Comorbidity linkage

Document the 'active' status of the condition even when controlled by medication to ensure the code is captured for risk adjustment purposes.

Example: Mixed hyperlipidemia (E78.2) remains stable on current regimen of Rosuvastatin 20mg and Vascepa 2g BID. Current LDL is 68 mg/dL and Triglycerides 145 mg/dL. Condition is chronic and requires ongoing pharmacological intervention to prevent cardiovascular events; medication adherence is confirmed.

Billing Focus: Ongoing status/Stability on medication

Incorporate laboratory evidence and specific laterality of physical findings like xanthomas to strengthen the diagnosis specificity.

Example: Patient presents with tuberous xanthomas located on the bilateral elbows, indicative of severe mixed hyperlipidemia (E78.2). Labs confirm Total Cholesterol 310 mg/dL and Triglycerides 420 mg/dL. High-intensity statin therapy initiated. Laterality of xanthomas and severity of lab values support the high-complexity medical decision-making required for this encounter.

Billing Focus: Physical exam findings and specific lab values

Relevant CPT Codes

Related Diagnoses

Hierarchy